CASI Pharmaceuticals Inc. (CASI)
Company Description
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally.
It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome.
Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors.
The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc.
It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH.
The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014.
CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Country | United States |
IPO Date | Jun 12, 1996 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 176 |
CEO | Dr. Wei-Wu He Ph.D. |
Contact Details
Address: 9620 Medical Center Drive Rockville, Maryland United States | |
Website | https://www.casipharmaceuticals.com |
Stock Details
Ticker Symbol | CASI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000895051 |
CUSIP Number | 14757U208 |
ISIN Number | US14757U2087 |
Employer ID | 58-1959440 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Wei-Wu He Ph.D. | Chairman & Chief Executive Officer |
Chunhua Wang | Chief Operating Officer |
Dr. James E. Goldschmidt Ph.D. | Chief Business Development Officer |
Hai Huang | Global Chief Commercial Officer & GM of CASI China |
Wei Gao | Senior Vice President & General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 03, 2025 | 6-K | Filing |
Apr 03, 2025 | 6-K | Filing |
Apr 01, 2025 | 424B5 | Filing |
Mar 31, 2025 | 20-F | Filing |
Mar 31, 2025 | 6-K | Filing |
Feb 10, 2025 | 6-K | Filing |
Feb 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Jan 21, 2025 | 6-K | Filing |
Dec 26, 2024 | 6-K | Filing |
Dec 23, 2024 | F-3/A | [Amend] Filing |